Collegium Pharmaceutical Inc (COLL)vsZoetis Inc (ZTS)
COLL
Collegium Pharmaceutical Inc
$23.04
+1.19%
HEALTHCARE · Cap: $724.14M
ZTS
Zoetis Inc
$71.33
-0.10%
HEALTHCARE · Cap: $29.50B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 1079% more annual revenue ($9.53B vs $808.21M). ZTS leads profitability with a 27.7% profit margin vs 5.9%. ZTS trades at a lower P/E of 11.7x. ZTS earns a higher WallStSmart Score of 58/100 (C).
COLL
Hold48
out of 100
Grade: D+
ZTS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.5%
Fair Value
$391.37
Current Price
$23.04
$368.33 discount
Margin of Safety
+11.0%
Fair Value
$144.59
Current Price
$71.33
$73.26 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Attractively priced relative to earnings
Every $100 of equity generates 83 in profit
Strong operational efficiency at 40.7%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Smaller company, higher risk/reward
5.9% margin — thin
Earnings declined 46.6%
Distress zone — elevated risk
Trading at 9.1x book value
1.2% earnings growth
Expensive relative to growth rate
Revenue declined 0.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : COLL
The strongest argument for COLL centers on Price/Book.
Bull Case : ZTS
The strongest argument for ZTS centers on P/E Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 27.7% and operating margin at 40.7%.
Bear Case : COLL
The primary concerns for COLL are Market Cap, Profit Margin, EPS Growth. Debt-to-equity of 2.75 is elevated, increasing financial risk.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.
Key Dynamics to Monitor
COLL profiles as a value stock while ZTS is a declining play — different risk/reward profiles.
ZTS carries more volatility with a beta of 0.73 — expect wider price swings.
COLL is growing revenue faster at 6.3% — sustainability is the question.
ZTS generates stronger free cash flow (538M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (58/100 vs 48/100), backed by strong 27.7% margins. COLL offers better value entry with a 88.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Collegium Pharmaceutical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?